Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Talwalkars Better Value Fitnes Share Price

₹ 1.45 0.00 (0.00%)

Mar 22 2021 12:00AM Miscellaneous NSE: TALWALKARS

Talwalkars Better Value Fitnes Share Price Update

As of the latest trading session, Talwalkars Better Value Fitnes share price is currently at 1.45, which is up by 0.00 from its previous closing. Today, the stock has fluctuated between 1.45 and 1.45. Over the past year, Talwalkars Better Value Fitnes has achieved a return of 31.81 %. In the last month alone, the return has been -17.61 %. Read More...

Talwalkars Better Value Fitnes Performance

Day Range

Low1.45 High1.45

1.45

52 Week Range

Low .00 High 1.45

1.45

Talwalkars Better Value Fitnes Share Price

533200

TALWALKARS

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

1.45 Prev. Close

1.45 Volume (Shares)

30842.00

Total traded value

.44

Upper Circuit

.00

Lower Circuit

.00

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Talwalkars Better Value Fitnes Fundamentals

(Standalone)

Market Cap (Cr)	0.0
PE Ratio (TTM)	0.0
Book Value / Share	0.0
Beta	0.0

ROE	0.0%
EPS (TTM)	0.0
Dividend Yield	0.0%
Net Profit Qtr (Cr)	0.0

Talwalkars Better Value Fitnes Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	JUN 2019 (Values in Cr)
Revenue	3.21
Operating Expense	21.47
Net Profit	-14.28
Net Profit Margin (%)	-444.85
Earnings Per Share (EPS)	-4.61
EBITDA	-1.87
Effective Tax Rate (%)	5.99

Particulars	MAR 2019 (Values in Cr)
Revenue	24.88
Operating Expense	21.41
Net Profit	8.55
Net Profit Margin (%)	34.36
Earnings Per Share (EPS)	2.76
EBITDA	16.61
Effective Tax Rate (%)	-26.68

Particulars	DEC 2018 (Values in Cr)
Revenue	17.95
Operating Expense	17.25
Net Profit	2.58
Net Profit Margin (%)	14.37
Earnings Per Share (EPS)	0.83
EBITDA	12.80
Effective Tax Rate (%)	32.12

Particulars	SEP 2018 (Values in Cr)
Revenue	18.24
Operating Expense	15.55
Net Profit	5.59
Net Profit Margin (%)	30.64
Earnings Per Share (EPS)	1.80
EBITDA	14.44
Effective Tax Rate (%)	-3.13

Particulars	JUN 2018 (Values in Cr)
Revenue	11.99
Operating Expense	13.93
Net Profit	1.38
Net Profit Margin (%)	11.50
Earnings Per Share (EPS)	0.44
EBITDA	10.05
Effective Tax Rate (%)	16.12

Particulars	MAR 2019 (Values in Cr)
Revenue	73.05
Operating Expense	68.15
Net Profit	18.09
Net Profit Margin (%)	24.76
Earnings Per Share (EPS)	5.84
EBITDA	53.90
Effective Tax Rate (%)	-2.76

Particulars	MAR 2018 (Values in Cr)
Revenue	57.28
Operating Expense	46.52
Net Profit	10.22
Net Profit Margin (%)	17.84
Earnings Per Share (EPS)	3.36
EBITDA	42.14
Effective Tax Rate (%)	26.73

Particulars	MAR 2017 (Values in Cr)
Revenue	49.35
Operating Expense	38.52
Net Profit	9.11
Net Profit Margin (%)	18.45
Earnings Per Share (EPS)	3.07
EBITDA	34.34
Effective Tax Rate (%)	34.35

Particulars	MAR 2016 (Values in Cr)
Revenue	229.22
Operating Expense	153.35
Net Profit	53.39
Net Profit Margin (%)	23.29
Earnings Per Share (EPS)	18.47
EBITDA	141.71
Effective Tax Rate (%)	35.33

Particulars	MAR 2015 (Values in Cr)
Revenue	200.22
Operating Expense	0.00
Net Profit	42.97
Net Profit Margin (%)	21.46
Earnings Per Share (EPS)	16.42
EBITDA	0.00
Effective Tax Rate (%)	0.00

Particulars	MAR 2018 (Values in Cr)
Book Value / Share	66.87
ROE %	4.33
ROCE %	6.05
Total Debt to Total Equity	0.76
EBITDA Margin	68.54

Particulars	MAR 2017 (Values in Cr)
Book Value / Share	66.87
ROE %	1.96
ROCE %	3.41
Total Debt to Total Equity	0.76
EBITDA Margin	63.67

Particulars	MAR 2016 (Values in Cr)
Book Value / Share	143.75
ROE %	15.73
ROCE %	15.18
Total Debt to Total Equity	0.94
EBITDA Margin	60.02

Particulars	MAR 2015 (Values in Cr)
Book Value / Share	105.74
ROE %	18.70
ROCE %	16.88
Total Debt to Total Equity	0.97
EBITDA Margin	56.26

Particulars	MAR 2014 (Values in Cr)
Book Value / Share	91.86
ROE %	17.72
ROCE %	16.63
Total Debt to Total Equity	0.82
EBITDA Margin	50.44

Particulars	MAR 2018 (Values in Cr)
Book Value / Share	65.46
ROE %	5.18
ROCE %	7.29
Total Debt to Total Equity	0.71
EBITDA Margin	74.13

Particulars	MAR 2017 (Values in Cr)
Book Value / Share	64.45
ROE %	3.01
ROCE %	4.22
Total Debt to Total Equity	0.72
EBITDA Margin	70.21

Particulars	MAR 2016 (Values in Cr)
Book Value / Share	139.08
ROE %	15.76
ROCE %	15.69
Total Debt to Total Equity	0.85
EBITDA Margin	62.07

Particulars	MAR 2015 (Values in Cr)
Book Value / Share	100.96
ROE %	17.35
ROCE %	16.58
Total Debt to Total Equity	0.88
EBITDA Margin	51.35

Particulars	MAR 2014 (Values in Cr)
Book Value / Share	88.25
ROE %	15.42
ROCE %	15.10
Total Debt to Total Equity	0.76
EBITDA Margin	50.97

Particulars	MAR 2018 (Values in Cr)
Cash & Short Term Investments	54.25
Total Assets	450.29
Total Liabilities	450.29
Total Equity	207.34
Share Outstanding	31004856
Price to Book Ratio	2.65
Return on Assets (%)	1.94
Return on Capital (%)	2.19

Particulars	MAR 2017 (Values in Cr)
Cash & Short Term Investments	8.13
Total Assets	378.87
Total Liabilities	378.87
Total Equity	198.64
Share Outstanding	29704856
Price to Book Ratio	4.13
Return on Assets (%)	1.61
Return on Capital (%)	1.96

Particulars	MAR 2016 (Values in Cr)
Cash & Short Term Investments	140.76
Total Assets	880.70
Total Liabilities	880.70
Total Equity	440.90
Share Outstanding	29704856
Price to Book Ratio	1.36
Return on Assets (%)	6.24
Return on Capital (%)	7.34

Particulars	MAR 2015 (Values in Cr)
Cash & Short Term Investments	46.55
Total Assets	666.38
Total Liabilities	666.38
Total Equity	290.39
Share Outstanding	26180888
Price to Book Ratio	3.68
Return on Assets (%)	6.91
Return on Capital (%)	8.1

Particulars	MAR 2014 (Values in Cr)
Cash & Short Term Investments	6.00
Total Assets	525.66
Total Liabilities	525.66
Total Equity	251.74
Share Outstanding	26180890
Price to Book Ratio	1.82
Return on Assets (%)	6.96
Return on Capital (%)	8.72

Particulars	MAR 2018 (Values in Cr)
Cash & Short Term Investments	53.94
Total Assets	419.53
Total Liabilities	419.53
Total Equity	202.96
Share Outstanding	31004856
Price to Book Ratio	2.65
Return on Assets (%)	2.43
Return on Capital (%)	2.78

Particulars	MAR 2017 (Values in Cr)
Cash & Short Term Investments	7.11
Total Assets	369.75
Total Liabilities	369.75
Total Equity	191.43
Share Outstanding	29704856
Price to Book Ratio	4.13
Return on Assets (%)	2.46
Return on Capital (%)	2.98

Particulars	MAR 2016 (Values in Cr)
Cash & Short Term Investments	120.02
Total Assets	803.18
Total Liabilities	803.18
Total Equity	413.12
Share Outstanding	29704856
Price to Book Ratio	1.36
Return on Assets (%)	6.64
Return on Capital (%)	7.77

Particulars	MAR 2015 (Values in Cr)
Cash & Short Term Investments	44.31
Total Assets	586.05
Total Liabilities	586.05
Total Equity	264.31
Share Outstanding	26180888
Price to Book Ratio	3.68
Return on Assets (%)	7.33
Return on Capital (%)	8.6

Particulars	MAR 2014 (Values in Cr)
Cash & Short Term Investments	4.15
Total Assets	478.99
Total Liabilities	478.99
Total Equity	231.05
Share Outstanding	26180890
Price to Book Ratio	1.82
Return on Assets (%)	6.97
Return on Capital (%)	8.68

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
KESORAM INDUSTRIES LTD	3.77	0.00	-3.68	117.14	3.66 / 11.79
MODI RUBBER LTD	104.70	11.67	0.47	262.17	86.05 / 156.75
THOMAS COOK (INDIA) LTD	131.40	24.89	4.02	6187.54	118.10 / 264.00
RAIN INDUSTRIES LIMITED	137.80	0.00	0.69	4634.90	117.30 / 196.95

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
FGP LTD.	8.98	47.26	2.87	10.68	5.85 / 14.18
KESORAM INDUSTRIES LTD	3.77	0.00	0.51	117.14	3.66 / 11.79
MPIL CORPORATION LTD.	620.00	0.00	2.36	35.34	506.00 / 1033.00
MODI RUBBER LTD	104.70	24.29	0.97	262.17	86.05 / 156.75

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 0.00
26 Days 0.00
10 Days 0.00
50 Days 0.00
12 Days 0.00
100 Days 0.00
20 Days 0.00
200 Days 0.00

0.0
PIVOT

First Resistance	0.0
Second Resistance	0.0
Third Resistance	0.0

First Support	0.0
Second Support	0.0
Third Support	0.0

RSI	0.0
MACD	0.0
Commodity Channel Index (CCI)	0.0

ADX	0.0
Williams % R	0.0

Talwalkars Better Value Fitnes Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

66.81 Promoter Holdings

32.89 FII

0.28 DII

0.0 Promoter Shares(Pledge Percentage)

69.83

Name	Category	Shares	Shares%
Prashant Sudhakar Talwalkar	Shareholding of Promoter and Promoter Group	2887780.0	9.31
Anant Ratnakar Gawande	Shareholding of Promoter and Promoter Group	2465200.0	7.95
Girish Madhukar Talwlakar	Shareholding of Promoter and Promoter Group	1840980.0	5.94
Harsha Ramdas Bhatkal	Shareholding of Promoter and Promoter Group	1550200.0	5.0
Laxmi Shivanand Mankekar	Public Shareholding	1258800.0	4.06
Anand Rathi Global Finance Limited	Public Shareholding	1243176.0	4.01
Mahavir Richab Investment Private Limited	Public Shareholding	958184.0	3.09
Shivanand Shankar Manekar Huf	Public Shareholding	694720.0	2.24
Idfc First Bank	Public Shareholding	585000.0	1.89
Vinayak R Gawande	Shareholding of Promoter and Promoter Group	566900.0	1.83
Better Value Leasing & Fiance Limited	Shareholding of Promoter and Promoter Group	467355.0	1.51
Madhukar Vishnu Talwalkar	Shareholding of Promoter and Promoter Group	420000.0	1.35
Pritam Umanath Rai	Public Shareholding	390901.0	1.26
Prasant Desai	Public Shareholding	333376.0	1.08
Rashid Ahmed Mirza ( Non Repeat )	Public Shareholding	322974.0	1.04

Talwalkars Better Value Fitnes

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2018-09-19	0.5	Final	2018-09-22	Equity shares	2017-09-21	1.5	Final	2017-09-23	Equity shares	2016-09-01	1.5	Final	2016-09-03	Equity shares	2015-09-03	1.5	Final	2015-09-05	Equity shares	2014-09-11	1.5	Final	2014-09-13	Equity shares	2013-08-01	1.5	Final	2013-08-03	Equity shares	2012-08-02	1.25	Final	2012-08-04	Equity shares	2011-08-04	1.0	Final	2011-08-06	Equity shares	2010-09-14	0.5	Final	2010-09-16	Equity shares

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read